Central Pharmaceuticals Ltd.
DDSE:CENTRALPHL8.40
BDT
+0.10
(+1.20%)
ISIN
BD0487CPL007
Return %
Stock
S&P 500
1Y
-3.45
14.20
3Y
-30.58
81.12
5Y
-49.70
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Munsur Ahamed
- Full Time Employees
- 76
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Apr 21, 2013
- Website
- centralphl1980.com
- Similar Companies
- Business
- Central Pharmaceuticals Ltd. is a Bangladesh-based pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of finished generic pharmaceutical formulations and human healthcare products. Founded in 1980 and headquartered in Dhaka, Bangladesh, the company operates within the domestic healthcare sector, supplying retail pharmacies, clinics, hospitals, and institutional healthcare providers across Bangladesh. The company's core product offerings span various dosage forms, including solid oral preparations such as tablets and capsules; liquid dosage formulations including oral solutions, syrups, and suspensions; and topical treatments including creams and ointments. Its commercial portfolio encompasses diverse therapeutic segments, including antibiotics, antibacterials, and anti-infective medications; analgesics, antipyretics, and anti-inflammatory drugs; gastrointestinal treatments, antacids, and proton pump inhibitors; antihistamines, antiallergics, and respiratory care products; cardiovascular agents; and multivitamin, mineral, and nutritional supplements. In recent developments, Central Pharmaceuticals Ltd. has focused on operational restructuring, regulatory compliance alignment, and facility overhaul initiatives to comply with Current Good Manufacturing Practice (cGMP) standards established by the Directorate General of Drug Administration (DGDA). The company has engaged in corporate and financial realignment to address capital requirements, resolve outstanding statutory and operational liabilities, and execute Balancing, Modernisation, Replacement, and Expansion (BMRE) programs aimed at modernizing production lines and resuming full-scale manufacturing and commercial distribution of its core pharmaceutical lines.